NCT05227339 is a Phase 2, PHASE3 clinical trial of RAE in Substance Use Disorders, sponsored by ContinueYou, LLC.

Who is sponsoring NCT05227339?

NCT05227339 is sponsored by ContinueYou, LLC.

What drugs are being tested in NCT05227339?

Interventions in NCT05227339: RAE.

What condition does NCT05227339 study?

NCT05227339 studies Substance Use Disorders, Treatment Adherence and Compliance.

Is NCT05227339 still recruiting?

NCT05227339 is currently completed. Last updated 25 July 2024.

Last reviewed 2024-07-25 · How we verify

NCT05227339

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RAE (Realize, Analyze, Engage)

Completed Phase 2, PHASE3 Last updated 25 July 2024

What this trial tests

Phase 2, PHASE3 trial testing RAE in Substance Use Disorders in 209 participants. Completed in 1 April 2024.

Timeline

22 February 2022

Primary endpoint
1 February 2024

1 April 2024

Quick facts

Lead sponsor	ContinueYou, LLC
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	209
Start date	22 February 2022
Primary completion	1 February 2024
Estimated completion	1 April 2024
Sites	1 location across United States

Drugs / interventions tested

Conditions studied

Substance Use Disorders — all drugs for Substance Use Disorders →
Treatment Adherence and Compliance — all drugs for Treatment Adherence and Compliance →

Sponsor

ContinueYou, LLC

Who can join

18 and older, any sex, with Substance Use Disorders or Treatment Adherence and Compliance. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study will evaluate the detection of digital biomarkers of stress, and drug craving in a population of individuals undergoing treatment for substance use disorder

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Evaluation of a digital tool for detecting stress and craving in SUD recovery: An observational trial of accuracy and engagement.
Carreiro S, Ramanand P, Taylor M, Leach R, et al · · 2024 · cited 8× · PMID 38917718 · DOI 10.1016/j.drugalcdep.2024.111353

Verify or expand the search:

Other recruiting trials for Substance Use Disorders

Currently open trials in the same condition.

NCT07219394 — Peer-Delivered Behavioral Activation in a CCBHC · NA · recruiting
NCT07529327 — Prevent Language Delays and Disorders Among Children of Caregivers With Substance Use Disorders With Community Groups an · NA · recruiting
NCT07281261 — tAN for Substance Use Disorder · NA · recruiting
NCT07210268 — Temporal Interference Methods for Addiction Treatment · NA · recruiting
NCT07146633 — Efficacy of an EMDR App for PTSD and SUD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05227339 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ContinueYou, LLC
Last refreshed: 25 July 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05227339.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing